Screening, Diagnosis, and Management of Gestational Diabetes Mellitus

ANDREW GARRISON, MD, Central City Community Health Center and the University of Utah, Salt Lake City, Utah

Gestational diabetes mellitus (GDM) affects approximately 6% of pregnancies in the United States, and it is increasing in prevalence. Pregnant women without known diabetes mellitus should be screened for GDM after 24 weeks of gestation. Treatment of GDM results in a statistically significant decrease in the incidence of preeclampsia, shoulder dystocia, and macrosomia. Initial management includes glucose monitoring and lifestyle modifications. If glucose levels remain above target values, pharmacologic therapy with metformin, glyburide, or insulin should begin. Antenatal testing is customary for women requiring medications. Induction of labor should not occur before 39 weeks in women with GDM, unless glycemic control is poor or another indication for delivery is present. Unless otherwise indicated, scheduled cesarean delivery should be considered only in women with an estimated fetal weight greater than 4,500 g. Women with a history of GDM are at high risk of subsequently developing diabetes. These patients should be screened six to 12 weeks postpartum for persistently abnormal glucose metabolism, and should undergo screening for diabetes every three years thereafter. (Am Fam Physician. 2015;91(7):460-467. Copyright © 2015 American Academy of Family Physicians.)
Treatment

**BENEFITS**

In the largest single trial of GDM treatment, investigators randomized 1,000 women with GDM to no treatment or to intervention with lifestyle modifications, blood glucose self-monitoring, and insulin therapy, if needed. Adverse perinatal outcomes—defined as infant death, shoulder dystocia, bone fracture, and/or nerve palsy—were 4% in the no treatment group compared with 1% in the intervention group ($P = .01$). A more recent systematic review and meta-analysis that included five randomized controlled trials and six cohort studies found that treating GDM results in a statistically significant decrease in the incidence of preeclampsia, shoulder dystocia, and macrosomia.  

**GLUCOSE MONITORING**

After receiving a diagnosis of GDM, patients should begin monitoring their blood glucose, initially with fasting levels and one- or two-hour postprandial levels. Fasting glucose levels should be less than or equal to 95 mg per dL (5.3 mmol per L), one-hour postprandial levels less than or equal to 140 mg per dL (7.8 mmol per L), and two-hour postprandial levels less than or equal to 120 mg per dL (6.7 mmol per L). No data suggest the superiority of one-hour vs. two-hour postprandial monitoring, so either is acceptable. Less intensive glucose monitoring is appropriate for women with GDM that is well controlled with diet and exercise.  

**LIFESTYLE CHANGES**

Initial treatment for GDM involves diet and activity modification. Women with GDM should receive individualized nutrition counseling from a registered dietitian, which commonly includes a recommendation to limit carbohydrate intake to 33% to 40% of calories. No high-quality data exist on the optimal diet for women with GDM. A Cochrane review of nine small trials comparing different types of dietary advice did not demonstrate any significant differences in perinatal outcomes. Some, but not all, trials suggest that a low glycemic index diet may result in improved glycemic control.  

Although the few trials evaluating the effects of exercise on women with GDM have yielded inconsistent results, aerobic exercise and resistance training clearly improve glycemic control in patients with diabetes. Exercise for 30 minutes most days of the week is recommended in addition to diet modification.  

<table>
<thead>
<tr>
<th>Table 1. Risk Factors for Gestational Diabetes Mellitus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk factor</td>
</tr>
<tr>
<td>Gestational diabetes mellitus in previous pregnancy</td>
</tr>
<tr>
<td>Body mass index &gt; 25 kg per m²</td>
</tr>
<tr>
<td>Ethnicity</td>
</tr>
<tr>
<td>Asian</td>
</tr>
<tr>
<td>Native American</td>
</tr>
<tr>
<td>Pacific Islander</td>
</tr>
<tr>
<td>Black</td>
</tr>
<tr>
<td>Hispanic</td>
</tr>
<tr>
<td>Diabetes in first-degree relative</td>
</tr>
<tr>
<td>Weight gain of more than 11 lb (5 kg) since 18 years of age</td>
</tr>
<tr>
<td>Maternal age older than 35 years</td>
</tr>
<tr>
<td>Gestational weight gain in excess of Institute of Medicine guidelines</td>
</tr>
<tr>
<td>Macrosomia in previous pregnancy</td>
</tr>
</tbody>
</table>

OR = odds ratio; RR = relative risk.
Information from references 6 through 10.

<table>
<thead>
<tr>
<th>Table 2. Adverse Outcomes Associated with Gestational Diabetes Mellitus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome</td>
</tr>
<tr>
<td>Maternal</td>
</tr>
<tr>
<td>Subsequent development of type 2 diabetes mellitus</td>
</tr>
<tr>
<td>Gestational hypertension</td>
</tr>
<tr>
<td>Preeclampsia</td>
</tr>
<tr>
<td>Cesarean delivery</td>
</tr>
<tr>
<td>Fetal</td>
</tr>
<tr>
<td>Shoulder dystocia/birth trauma</td>
</tr>
<tr>
<td>Macrosomia</td>
</tr>
<tr>
<td>Subsequent adolescent and childhood overweight</td>
</tr>
<tr>
<td>Birth defects</td>
</tr>
<tr>
<td>Hyperbilirubinemia</td>
</tr>
<tr>
<td>Hypoglycemia</td>
</tr>
</tbody>
</table>

*—Study heterogeneity precludes reliable estimate of increased risk of metabolic complications.
Information from references 5, 11, and 12.
A week is a reasonable goal for most patients with GDM.

Attention to maternal weight gain is also important in minimizing the risk of fetal macrosomia. Maternal obesity, excess gestational weight gain, and GDM are independent and additive risk factors for macrosomia. For example, among women with obesity, GDM, and gestational weight gain greater than 40 lb (18.1 kg), the risk of fetal macrosomia is nearly 40%.

Although no specific intervention has been shown to prevent excess gestational weight gain, clinicians can counsel patients using the Institute of Medicine’s 2009 recommendations on gestational weight gain, Weight Gain During Pregnancy: Reexamining the Guidelines.

**ORAL MEDICATIONS**

An elevated blood glucose level despite lifestyle modifications is an indication for pharmacologic therapy. Although insulin has historically been the standard therapy for women with uncontrolled GDM, oral medications are now appropriate first-line therapies as well. Options for oral medications include metformin (Glucophage) and glyburide. Although neither glyburide nor metformin has been approved by the U.S. Food and Drug Administration for the treatment of GDM, both are pregnancy category B. Metformin and glyburide cross the placenta but have not been associated with birth defects or short-term adverse neonatal outcomes. However, data on long-term

---

**Table 3. Screening and Diagnostic Criteria for Gestational Diabetes Mellitus**

**Two-step screening:**
Administer a nonfasting 50-g oral glucose challenge test.

If the value meets or exceeds the thresholds below and is ≤ 200 mg per dL (11.1 mmol per L), administer a 100-g oral glucose tolerance test.

Diagnose GDM if two or more values on a 100-g test meet or exceed the thresholds below.

The American Diabetes Association does not consider a value > 200 mg per dL on a 50-g oral glucose challenge test to be necessarily diagnostic of GDM; however, it is reasonable to treat these patients empirically as if they have GDM (without performing a 100-g oral tolerance test) because they require insulin during pregnancy more often than patients with GDM diagnosed using the 100-g test.

<table>
<thead>
<tr>
<th>Test</th>
<th>Time</th>
<th>Threshold for abnormal result</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>50-g oral glucose challenge test</td>
<td>1 hour</td>
<td>130 mg per dL (7.2 mmol per L) or 135 mg per dL (7.5 mmol per L) or 140 mg per dL (7.8 mmol per L)</td>
<td>Use of any threshold value is acceptable. A cutoff of 130 mg per dL is more sensitive (99% vs. 85%) but less specific (77% vs. 86%) compared with a cutoff of 140 mg per dL.</td>
</tr>
</tbody>
</table>

**Test**

**Time**

**Threshold for abnormal result**

**Comments**

---

**Threshold for abnormal result**

**Test**

**Time**

**Carpenter and Coustan criteria**

**National Diabetes Data Group criteria**

**Comments**

---

**One-step screening:**
Administer a fasting 75-g oral glucose tolerance test.

Diagnose GDM if one or more thresholds are met or exceeded.

<table>
<thead>
<tr>
<th>Test</th>
<th>Time</th>
<th>Threshold for abnormal result</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>75-g oral glucose tolerance test</td>
<td>Fasting</td>
<td>92 mg per dL (5.1 mmol per L)</td>
<td>Compared with the two-step approach, the one-step approach results in a higher prevalence of GDM (6% vs. 15% to 20%).</td>
</tr>
</tbody>
</table>

GDM = gestational diabetes mellitus.

Information from references 1, and 13 through 16.
metabolic effects on children with in utero exposure are limited. Clinicians may consider counseling patients on the lack of long-term safety data for these medications.

No consensus exists on the threshold values above which medications should be prescribed; therefore, clinicians can consider gestational age, frequency and severity of blood glucose elevations, fetal growth, and patient preference. One approach is to begin pharmacologic therapy if more than two values at the same meal during a two-week period are above target by more than 10 mg per dL (0.6 mmol per L). Another approach is to initiate medications if 50% of the values in a given week are elevated.

Glycemic control, maternal and neonatal outcomes, and adverse effects are similar among patients treated with oral hypoglycemic medications vs. insulin, although glyburide may be associated with a lower failure rate (i.e., need for insulin therapy) than metformin. Metformin is typically started at 500 mg once daily with food, and titrated to a maximum dosage of 2,500 mg per day (given in divided doses with meals). Glyburide is initiated at 2.5 mg once per day one hour before eating, and increased to a maximum of 10 mg twice per day, as needed. Between 15% and 40% of women initially prescribed oral medications for GDM ultimately require insulin.

INSULIN

Insulin is required in women who have uncontrolled blood glucose levels despite lifestyle changes and use of oral medications, and in women who elect to avoid a trial of oral medications. Insulin does not cross the placenta; rapid-, intermediate-, and long-acting insulins are considered safe for use in pregnancy.

One approach to starting insulin therapy is to calculate a total daily dosage of 0.7 to 1.0 units per kg. Half of the total daily requirement is administered as a single dose of long-acting insulin (e.g., glargine [Lantus], detemir [Levemir]), and the other half is administered in three divided doses at mealtimes as rapid-acting insulin (e.g., lispro [Humalog], aspart [Novolog]). Insulin dosing should be individualized and adjusted as needed. An algorithm for the management of GDM is presented in Figure 1.

Fetal Assessment

There is no consensus on the optimal approach to fetal surveillance in pregnancies complicated by GDM. Antenatal testing in women who have GDM that is well controlled without medications is not beneficial because the risk of stillbirth is not increased in this population. Antenatal testing is commonly performed in women who require medication for GDM, although data supporting this practice are limited to older observational studies. The American College of Obstetricians and Gynecologists (ACOG) recommends that clinicians perform antenatal testing in accordance with local practice patterns. Such testing could include twice-weekly nonstress tests or weekly modified biophysical profiles beginning at 32 to 34 weeks of gestation.

The role of ultrasonography in pregnancies complicated by GDM varies among clinicians and institutions. Some physicians obtain serial ultrasonography (separated by at least four weeks) to monitor fetal growth in patients with GDM. Several small trials have found that instituting tighter glycemic control for women with accelerated fetal growth may result in a lower incidence of large-for-gestational-age infants. However, larger studies are needed before routine use of ultrasonography to guide management of GDM can be recommended, especially because undergoing third-trimester ultrasonography may be an independent risk factor for cesarean delivery.

Other physicians perform ultrasonography near the end of pregnancy to assess the risk of fetal macrosomia. However, a sonographically estimated fetal weight of greater than 4,000 g (8 lb, 13 oz) is only modestly predictive of an actual fetal weight greater than 4,000 g, with a positive likelihood ratio of 5.7 (95% confidence interval [CI], 4.3 to 7.6) and a negative likelihood ratio of 0.48 (95% CI, 0.38 to 0.60). Among fetuses weighing more than 4,000 g, clinical estimates (using Leopold maneuvers and
Management of Gestational Diabetes Mellitus

Presentation for antenatal care

Risks for preexisting diabetes mellitus?

No
Yes

Screen for diabetes using fasting glucose level, A1C level, or two-hour oral glucose tolerance test

Normal
Abnormal

Screen at 24 to 28 weeks for gestational diabetes

Manage as preexisting diabetes

Routine care

Begin blood glucose self-monitoring
Lifestyle modifications
Close follow-up

Glucose level: fasting $\leq$ 95 mg per dL (5.3 mmol per L), one-hour postprandial $\leq$ 140 mg per dL (7.8 mmol per L), or two-hour postprandial $\leq$ 120 mg per dL (6.7 mmol per L)?

No
Yes

Consider initiation of oral agent or insulin
Follow up in one to two weeks

Go to A

A Glucose controlled?

No
Yes

Initiate and/or intensify pharmacotherapy as needed
Continue present management strategy

Consider antenatal testing at 32 to 34 weeks if using oral agents or insulin

Poor glycemic control despite medication use or another indication for delivery (such as preeclampsia) exists?

No
Yes

Plan for delivery at > 39 weeks
Induction of labor as clinically indicated

Estimated fetal weight $> 4,500$ g (9 lb, 14 oz)?

No
Yes

Plan for vaginal birth
Counsel on potential risks and benefits of scheduled cesarean delivery

Monitor glucose level intrapartum and treat as needed

Generally discontinue oral agents and/or insulin after delivery

Screen for abnormal glucose metabolism at six to 12 weeks postpartum and every three years thereafter

Information from references 1 and 2.

Fundal height measurements) are as predictive of macrosomia as ultrasonography, and appear comparable to the estimates of parous women of their baby’s size. ACOG recommends that clinicians assess fetal growth in patients with GDM late in the third trimester, stating that ultrasonography or clinical examination is appropriate.

Timing and Route of Delivery

The optimal timing of delivery in pregnancies complicated by GDM is unclear. Given the neonatal risks associated with early term births, induction of labor before 39 weeks should occur only if glycemic control remains poor despite medication use, or if another indication for delivery is present.

Limited evidence suggests that induction of women with GDM at 39 weeks, compared with further expectant management, is associated with a lower risk of macrosomia and shoulder dystocia without increasing the risk of cesarean delivery. Expectant management beyond 39 weeks is also associated with an increased risk of stillbirth (relative risk $= 1.8; 95\%$ CI, 1.2 to 2.6), although the
absolute risk remains low (5.7 per 10,000 deliveries). Although ACOG has not made an evidence-based recommendation on the ideal timing of delivery for patients with GDM, many physicians offer induction between 39 and 40 weeks, particularly for patients with other risks of stillbirth.

For women with GDM and an estimated fetal weight greater than 4,500 g (9 lb, 14 oz), scheduled cesarean delivery, compared with vaginal birth, reduces the risk of permanent brachial plexus injury, although the number needed to treat may be as high as 588. It is reasonable to offer a scheduled cesarean delivery to these patients, although they should be counseled on the difficulty of accurately estimating fetal weight and the risks associated with cesarean delivery in the index pregnancy and future pregnancies.2

**Intrapartum and Postpartum Management**

Maintaining euglycemia during labor and delivery can minimize risks of neonatal hypoglycemia and acidosis. Women with diet-controlled GDM rarely require intrapartum insulin. A variety of protocols exist to guide intrapartum management of blood glucose among women receiving insulin, but in general, glucose levels should be monitored every one to two hours during active labor, and 5% dextrose or insulin infused as needed to maintain glucose levels between 70 and 110 mg per dL (3.9 and 6.1 mmol per L). It may be reasonable to have women with GDM use only one-half of their usual dose of long-acting insulin the day of delivery. Clinicians should prepare to manage shoulder dystocia at the time of delivery and exercise caution when considering an operative vaginal delivery.

Women with GDM rarely need oral agents or insulin immediately after delivery. Before discharge, it is reasonable to confirm that fasting glucose values are normal. However, short- and long-term follow-up is critical. Women with GDM should undergo screening at six to 12 weeks postpartum, and every three years thereafter, for abnormal glucose metabolism. Women with GDM should undergo screening at six to 12 weeks postpartum, and every three years thereafter, for abnormal glucose metabolism. GDM is a significant risk factor for subsequent development of diabetes. In high-risk populations, diabetes develops in up to 50% of women with GDM. Women with a history of GDM should be screened every three years for overt diabetes. Breastfeeding may reduce the subsequent risk of developing type 2 diabetes in women who had GDM. Any form of contraception that is otherwise medically appropriate can be used by women with a history of GDM.

---

**SORT: KEY RECOMMENDATIONS FOR PRACTICE**

<table>
<thead>
<tr>
<th>Clinical recommendation</th>
<th>Evidence rating</th>
<th>References</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening for GDM should occur after 24 weeks of gestation in all women without known diabetes mellitus.</td>
<td>B</td>
<td>13</td>
<td>USPSTF recommendation based on systematic reviews and meta-analyses</td>
</tr>
<tr>
<td>Initial management of GDM involves dietary changes, increased physical exercise, and blood glucose self-monitoring.</td>
<td>C</td>
<td>2, 20</td>
<td>Systematic review and meta-analysis of inconsistent studies; consensus guideline</td>
</tr>
<tr>
<td>Target glucose values in women with GDM are ≤ 95 mg per dL (5.3 mmol per L) with fasting, ≤ 140 mg per dL (7.8 mmol per L) one-hour postprandial, or ≤ 120 mg per dL (6.7 mmol per L) two-hour postprandial.</td>
<td>C</td>
<td>2, 21</td>
<td>Recommendation from consensus guideline; one small randomized controlled trial</td>
</tr>
<tr>
<td>Pharmacologic therapy with metformin (Glucophage), glyburide, or insulin is appropriate for women with GDM whose glucose values are above goal despite lifestyle modifications.</td>
<td>C</td>
<td>2, 20, 35</td>
<td>Systematic review and meta-analysis of inconsistent studies; consensus guideline</td>
</tr>
<tr>
<td>Women with GDM should be screened at six to 12 weeks postpartum, and every three years thereafter, for abnormal glucose metabolism.</td>
<td>C</td>
<td>1, 2</td>
<td>Consensus guideline</td>
</tr>
</tbody>
</table>

GDM = gestational diabetes mellitus; USPSTF = U.S. Preventive Services Task Force.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.
Gestational Diabetes

Data Sources: A PubMed search was completed in Clinical Queries using the key term gestational diabetes. This search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Also searched were the Agency for Healthcare Research and Quality evidence reports, the U.S. Preventive Services Task Force, the Cochrane database, DynaMed, and Essential Evidence Plus. Search dates: January 2014, and December 19, 2014.

The Author
ANDREW GARRISON, MD, is a physician at Community Health Centers, Inc., and an adjunct faculty member in the Department of Family and Preventive Medicine at the University of Utah School of Medicine in Salt Lake City.

Address correspondence to Andrew Garrison, MD, University of Utah, Central City Community Health Center, 461 S. 400 E., Salt Lake City, UT 84111 (e-mail: Andrew.garrison@hsc.utah.edu). Reprints are not available from the author.

REFERENCES


